Cover Image
市場調查報告書

Melior Discovery, Inc. :產品平台分析

Melior Discovery, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 257877
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
Melior Discovery, Inc. :產品平台分析 Melior Discovery, Inc. - Product Pipeline Review - 2014
出版日期: 2014年09月22日 內容資訊: 英文 31 Pages
簡介

Melior Discovery, Inc.提供需要評估藥物動力學的其他製藥公司及生物製藥公司一個鎖定適用前臨床階段及開發階段的藥劑候補之藥理學平台。該公司網羅了發炎、免疫學、糖尿病、代謝症候群、皮膚科學、循環系統疾病、消化器官疾病、精神疾病、神經病變、神經退化性疾病等領域。

本報告提供Melior Discovery, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Melior Discovery, Inc.的基本資料

  • Melior Discovery, Inc.概要
  • 主要資訊
  • 企業資料

Melior Discovery, Inc.:R&D概要

  • 主要的治療範圍

Melior Discovery, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Melior Discovery, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • IND/CTA所申請的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Melior Discovery, Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Melior Discovery, Inc.:藥物簡介

  • MLR-1023
  • MLR-1017
  • MLR-1130
  • MLR-1362
  • Insulin Analogs
  • MLR-1045

Melior Discovery, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Melior Discovery, Inc.:最近的開發平台趨勢

Melior Discovery, Inc.:暫停中的計劃

Melior Discovery, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • MLR-1023
  • MLR-1045
  • MLR-1130
  • MLR-1362

Melior Discovery, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06358CDB

Summary

Global Markets Direct's, 'Melior Discovery, Inc. - Product Pipeline Review - 2014', provides an overview of the Melior Discovery, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Melior Discovery, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Melior Discovery, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Melior Discovery, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Melior Discovery, Inc.'s pipeline products

Reasons to buy

  • Evaluate Melior Discovery, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Melior Discovery, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Melior Discovery, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Melior Discovery, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Melior Discovery, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Melior Discovery, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Melior Discovery, Inc. Snapshot
    • Melior Discovery, Inc. Overview
    • Key Information
    • Key Facts
  • Melior Discovery, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Melior Discovery, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Melior Discovery, Inc. - Pipeline Products Glance
    • Melior Discovery, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Melior Discovery, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Melior Discovery, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Melior Discovery, Inc. - Drug Profiles
    • MLR-1023
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLR-1017
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLR-1130
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLR-1362
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Insulin Analogs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MLR-1045
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Melior Discovery, Inc. - Pipeline Analysis
    • Melior Discovery, Inc. - Pipeline Products by Target
    • Melior Discovery, Inc. - Pipeline Products by Route of Administration
    • Melior Discovery, Inc. - Pipeline Products by Molecule Type
    • Melior Discovery, Inc. - Pipeline Products by Mechanism of Action
  • Melior Discovery, Inc. - Recent Pipeline Updates
  • Melior Discovery, Inc. - Dormant Projects
  • Melior Discovery, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • MLR-1023
      • MLR-1045
      • MLR-1130
      • MLR-1362
  • Melior Discovery, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Melior Discovery, Inc., Key Information
  • Melior Discovery, Inc., Key Facts
  • Melior Discovery, Inc. - Pipeline by Indication, 2014
  • Melior Discovery, Inc. - Pipeline by Stage of Development, 2014
  • Melior Discovery, Inc. - Monotherapy Products in Pipeline, 2014
  • Melior Discovery, Inc. - Phase II, 2014
  • Melior Discovery, Inc. - IND/CTA Filed, 2014
  • Melior Discovery, Inc. - Preclinical, 2014
  • Melior Discovery, Inc. - Discovery, 2014
  • Melior Discovery, Inc. - Unknown, 2014
  • Melior Discovery, Inc. - Pipeline by Target, 2014
  • Melior Discovery, Inc. - Pipeline by Route of Administration, 2014
  • Melior Discovery, Inc. - Pipeline by Molecule Type, 2014
  • Melior Discovery, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Melior Discovery, Inc. - Recent Pipeline Updates, 2014
  • Melior Discovery, Inc. - Dormant Developmental Projects,2014
  • Melior Discovery, Inc. - Discontinued Pipeline Products, 2014

List of Figures

  • Melior Discovery, Inc. - Pipeline by Top 10 Indication, 2014
  • Melior Discovery, Inc. - Pipeline by Stage of Development, 2014
  • Melior Discovery, Inc. - Monotherapy Products in Pipeline, 2014
  • Melior Discovery, Inc. - Pipeline by Top 10 Target, 2014
  • Melior Discovery, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Melior Discovery, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Melior Discovery, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top